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Objectives. The aim of this study was to analyse the composition of amyloid mass and the plasmacytic infiltrate of localized
amyloidosis of the upper aerodigestive tract. Methods. Biopsy materials were studied by light microscopy, immunohistochemistry
(IHC), and mRNA in situ hybridization (mRNA-ISH). The amyloid mass was also analysed with high-performance liquid
chromatography mass spectrometry- (HPLC-MS-) based proteomics. Results. Nodular and diffuse forms of amyloid deposition
were detected. IHC analysis revealed λ-light chain (LC) in two cases, κ-LC in one case. The remaining two were positive with
both. Proteins, well known from other amyloidoses like amyloid A (AA), prealbumin/transthyretin (PA), apolipoprotein A-I
(ApoAI), and amyloid P component (APC), and also keratin were found with variable intensities in the cases. HPLC-MS
revealed dozens of proteins with both LCs in all the lesions but sometimes with surprisingly small intensities. mRNA-ISH
analysis revealed identical λ and κ dominance and only one normal κ/λ cell ratio. Conclusion. Cellular infiltrate and protein
components in the amyloid showed congruent results in all but one case. The only exception with normal cell ratio and λ-
dominant amyloid could be originated from the different protein-secreting activity of plasma cell clones. HPLC-MS analysis
explored both LCs in all the amyloid in variable amount, but other proteins with much higher intensities like keratins,
apolipoprotein A-IV (ApoAIV), were also detected. Proteins like AA, PA, ApoAI, and APC, previously known about amyloid-
forming capability, also appeared. This indicates that localized amyloid in the upper aerodigestive tract is not a homogenous
immunoglobulin mass but a mixture of proteins. The sometimes very low light chain intensities might also suggest that not all
the localized amyloidosis cases of the upper aerodigestive tract are of convincingly AL type, and the analysis of the cellular
infiltrate might indicate that not all are monoclonal.
1. Introduction
Localized amyloidosis is a rare disease with deposition of
amyloid material in a restricted area of an anatomical region,
which results in a tissue mass. This “mass effect” may mimic
tumour growth explaining the other name of the lesion:
amyloid tumour. The type of the protein locally deposited
is variable and related to the anatomical site: Aβ (β protein
precursor) in the central nervous system, AL (light chain)
in the upper aerodigestive tract, AIAPP (islet amyloid poly-
peptide) in the pancreas islets, ASem1 (semenogelin) in the
seminal vesicles, AGal7 (galectin 7) and AIns (insulin) in
the skin, APro (prolactin) in the pituitary gland, and AANF
(atrial natriuretic factor) in the atrial myocardium just to
mention some of them [1]. The AL type is by far the most fre-
quent localized amyloidosis [2]. Despite the relatively large
number of case reports on localized AL amyloidosis, the
majority of which mainly summarize the clinicopathological
characteristics of the disease; little is known about the patho-
genesis and the composition of the amyloid material. AL
amyloid is supposed to be the product of locally accumulated
plasma cells, which are regarded to be of monoclonal origin.
Hindawi
Analytical Cellular Pathology
Volume 2019, Article ID 6165140, 9 pages
https://doi.org/10.1155/2019/6165140
In addition, very frequently just few plasma cells could be
identified in the biopsy material which led to the “suicide
neoplasm” theory [3]. Moreover, amino acid sequence anal-
ysis of amyloid light chain proved the monoclonal nature of
the protein (either κ or λ) in those cases examined [4, 5]. If
it was abundant, the cellular component in the lesions was
also analysed and frequently found to be monoclonal or obvi-
ously neoplastic [6–11]. Polyclonal nature of the infiltrating
plasma cells was also found in some cases which seemingly
contradicts the neoplastic nature of the lesion [8]. Few years
ago, as a new method, mass spectrometry (MS) was
introduced in the amyloid protein analysis of the systemic
diseases, and in a recent study, MS was combined with the
standard immunohistochemistry (IHC) to identify the
nature of the protein [12, 13]. 100% concordance was found
between the two methods [14]. Further combination of MS
with laser capture microscopy made the diagnostics of amy-
loidosis even more effective [15]. IHC analysis of some of
the localized amyloidosis cases of our departmental archive
indicated the presence of both light chains in the amyloid
material, which raised the possibility that the AL amyloid
deposits could also be polyclonal products. The composition
of the amyloid material and the cellular component in
localized disease are not extensively studied; therefore, we
decided to extend the immunohistochemistry and com-
plete the study with mRNA in situ hybridization and pro-
teomics using nano-HPLC-MS to determine the clonality
of the cellular infiltrate and to further analyse the amyloid
material in our cases.
2. Materials and Methods
2.1. Patients and Biopsy Samples. Five patients (four male and
one female) with localized amyloidosis of the upper aerodi-
gestive tract were collected from the archive of the pathology
department. Three lesions appeared in the larynx (vocal cord,
vocal fold, and supraglottic region) and two (one each) in the
epipharynx and the oral cavity (palate). The age range was
31-62 years, and in all the cases, the main clinical symptom
was a mass-like lesion in the affected region suggesting
malignancy (Table 1). Despite this, none of the patients
developed systemic or malignant disease according to the
clinical data explored.
2.2. Histopathological Evaluation. Excision biopsies from the
five cases were analysed. After the standard preanalytical
processes (fixation in 6% buffered formalin, dehydration,
and paraffin embedding of the tissue samples), 4 μm thick
sections were cut and standard haematoxylin-eosin (HE)
stainings were prepared for diagnostic purposes. The
Congo red staining was performed with and without
KMnO4-trypsin pretreatment according to Romhanyi’s
method, and the slides were studied in polarized light [16].
Kossa reaction was performed when calcification of the amy-
loid material was seen. Parallel sections were used for prote-
omic analysis (see below).
2.3. Immunohistochemistry. κ and λ immunohistochemical
stainings (monoclonal antibodies, Thermo Scientific, L1C1
and HP6054 clones in dilutions of 1 : 4000 and 1 : 2000,
respectively, at 60 minutes in room temperature) were used
to identify the type of light chains in the amyloid material
and in the plasma cells. DAKO Autostainer Link 48 platform
was used for the reactions, and the Envision Flex TRS high
pH (DAKO) antigen retrieval solution was selected for anti-
gen retrieval. The pretreatment was performed at pH 9 for
20 minutes. Histols MR and DAB Histols MR (30 and 10
minutes, respectively, at room temperature) were used as
developing system. CD38 mouse monoclonal antibody
(clone SPC32, Leica Biosystems) was used to identify plasma
cells. The staining was run at the Leica Bond-Max platform
for 15 minutes at 1 : 150 antibody dilution, and the develop-
ing system was Bond Polymer Refine Detection Kit (Leica
Biosystems) with DAB chromogen. The pretreatment was
performed with Bond Epitope Retrieval Solution 1 (Leica
Biosystems) at pH 6 for 20 minutes. The same platform,
pretreatment, and developing system were used for the pri-
mary antibodies against amyloid A (AA, mouse monoclonal
anti-human amyloid A, mc1, DAKO, 1 : 200, pH 9, 20
minutes), prealbumin/transthyretin (PA, polyclonal rabbit
anti-human prealbumin, DAKO, 1 : 500, pH 6, 20 minutes),
apolipoprotein A-I (ApoAI, mouse monoclonal ApoAI,
clone 6001, Thermo Fisher, 1 : 1000, pH 6, 20 minutes),
amyloid P component (APC, rabbit polyclonal serum
amyloid P, Thermo Fisher, 1 : 200, pH 9, 20 minutes), and
pan-cytokeratin (mouse monoclonal AE1-AE-3, DAKO,
1 : 300, pH 9, 20 minutes).
2.4. mRNA In Situ Hybridization. The automated Leica
Bond-Max system was used in this assay as well. 4 μm thick
FFPE sections were deparaffinised at 60°C for 30 minutes in
Bond Dewax Solution and digested with proteinase-K
(Enzyme Pretreatment kit) at 37°C for 15 minutes. κ and also
λ mRNA in situ hybridizations (mRNA-ISH) were per-
formed on all samples using the Bond Ready-to-Use ISH
kit at 37°C for 120 minutes. After a short period of endoge-
nous peroxidase blocking for 5 minutes, incubation with
Anti-Fluorescein Antibody (15 minutes, room temperature)
and Bond Polymer Refine Detection system DAB were used
for detecting the signals (all from Leica Biosystems).
2.5. Digitization of mRNA-ISH Slides and Image Analysis of
Cellular Infiltrate. κ and λ mRNA-ISH stained slide pairs
cut from the same paraffin blocks of the cases were digitized
(Pannoramic MIDI, 3DHistech) consecutively, and the
image analysis was performed on the virtual slides. The aim
of the analysis was to determine the ratio of the κ- and λ-pos-
itive cells. Two to three equivalent annotations were made in
the slide pairs by CaseViewer (3DHistech) in the cell-rich
areas. PatternQuant module (3DHistech) was used to select
the corresponding tissue areas and to exclude the amyloid
material and the cell-free fields. Plasma cells positive for κ
or λ mRNA were counted by CISH-RNAQuant module
(3DHistech) independently of their staining intensity in all
the annotations after visual adjustment. The ratio of κ/λ-pos-
itive plasma cells was calculated in percent (see Table 1).
Normal κ/λ ratio was determined as 2/1 (67%/33%) accord-
ing to a former publication [17].
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2.6. Nano-HPLC-MS(MS) and Proteomic Analysis. Unstained
formalin-fixedparaffin-embedded (FFPE) slideswere dewaxed,
and antigen retrieval was performed as previously described
[18]. Tissue sections were dried, and regions corresponding
to amyloid mass in the HE-stained slides were scraped off
using a needle and placed in 50 μL lysis buffer (4% SDS in
100mM Tris pH7.6). Proteins were precipitated using etha-
nol and digested in solution [19]. The peptides were desalted
using Pierce C18 spin columns (Thermo Scientific, Waltham,
MA, USA). Discovery proteomics was performed using an
Ultimate 3000 nanoRSLC system (Dionex, Waltham, MA,
USA) coupled to a high-resolution Bruker Maxis II ETD
Q-TOF mass spectrometer (Bruker Daltonics, Bremen,
Germany) via a CaptiveSpray NanoBooster insource [20].
Samples were dissolved in 20 μL of 2% AcN, 0.1% FA out
of which 6 μL was analysed. Protein identification was
performed using the Mascot server v.2.5 (Matrix Science,
London, UK). Samples were matched against the Swissprot
human database (2015_08) applying the following search
parameters: trypsin enzyme, maximum 2 missed cleavages,
7 ppm peptide tolerance, 0.05Da fragment mass tolerance,
and carbamidomethylation as fixed modification and car-
bamyl (K, N-term), deamidation (N, Q), and oxidation
as variable modifications. Proteins with a minimum of
two identified unique peptides were accepted. Label-free
quantification was performed using MaxQuant software
version 1.5.3.30 [21].
3. Results
3.1. Histopathological Analysis. In all examined cases, the
largest proportion of the overall tissue volume was formed
by the amyloid material. Structurally, the deposition
appeared in the form of a diffuse mass infiltrating and
embedding the surrounding tissue elements like glands and
collagen fibres, or it formed concentrically laminated nodules
sitting side by side (Table 1). In cases 1, 4, and 5, the two pat-
terns were mixed with each other (Figures 1(a) and 1(b)). All
the cases showed moderate to strong Congo red staining and
apple-green birefringence in polarized light even after
KMnO4-trypsin pretreatment (Figure 1(c)). In some of the
cases (patients 1 and 4), giant cell reaction around and focal
calcification within the amyloid material were also seen
(Figure 1(b)). Although a variable number of white blood
cells (plasma cells, lymphocytes) were detected in the sam-
ples by the HE and CD38 staining, the amount of the cellular
infiltrate was only a fraction of the amyloid material. In some
cases, the cellular component was very scarce and the κ and λ
immunohistochemical analyses failed to identify the clonality
of the population. Unambiguous result was found only in
case 4 which showed diffuse strong κ positivity in the plasma
cell population, and just a few reactive λ-positive cells were
detected. In two of the cases (patients 1 and 5), both κ and
λ antibodies were positive in the amyloid deposits; in the
other two cases (patients 2 and 3), only the λ light chain
could be detected while in the remaining one (patient 4) only
κ was convincingly positive in the deposits (Table 1). The
intensity of the immunostaining was variable, and the pat-
tern was similarly laminated (stronger and weaker layers
alternating with each other) in the nodules as previously
seen in HE (Figure 1(d)). The four proteins (AA, PA,
ApoAI, and APC) partly known because of their amyloi-
dogenic potential were frequently found in the amyloid
mass of the patients 1, 2, 4, and 5 (Table 2). The intensity
of the reactions was also variable even in the same sample
frequently highlighting the structure of the nodules
(Figures 1(e)–1(h)). APC showed a strong peripheral stain-
ing pattern (Figure 1(f)). Weak immunoreaction of pan-
cytokeratin was detected in cases 1 and 5, but no reaction
was seen in case 4 (Table 2). Due to the small size of the
original biopsy, no tissue remained in cases 2 and 3 in
order to examine the protein expressions above.
3.2. mRNA In Situ Hybridization. Analysis of the identical
fields of mRNA-ISH specimens revealed κ- or λ-dominant
plasma cell populations in four cases (Table 1). In patients
1, 3, and 5, λ-dominant cell infiltrate was seen with 19% vs.
81%, 5% vs. 95%, and 16% vs. 84% κ/λ ratios, respectively.
In patient 4, κ-dominant population was observed: the κ/λ
ratio was 86% vs. 14%. In patient 2, this ratio was 67% vs.
33%, which is similar to the normal human reactive lym-
phoid population with its 2 : 1 ratio [17]. Dominance of
one of the plasma cell types was unequivocal in all but
one case (patient 2), which qualifies them as rather clonal
Table 1: Characteristics of localized amyloidosis cases of the upper aerodigestive tract. Congo staining was performed with and without
KMnO4-trypsin pretreatment, and the slides were analysed also in polarized light. The type of cellular infiltrate and the structural and
immunohistochemical characteristics of amyloid deposition were also analysed. Patient: m: male; f: female; Congo: staining with/without
KMnO4-trypsin pretreatment; IHC: κ and λ immunohistochemical staining feature of the accumulated amyloid; mRNA-ISH: messenger
RNA in situ hybridization of plasma cells in the cellular infiltrate.
Patient Anatomic site Macroscopy Congo Amyloid Microscopy IHC mRNA-ISH
1 61, m Larynx (vocal+ventricular fold)
Verrucous
mass
+/+
Diffuse+laminated
concentric
ly+plasma cell κ+, λ+ κ/λ: 19%/81% (1 : 4)
2 44, m Epipharynx Cyst +/+ Diffuse ly+plasma cell κ−, λ+ κ/λ: 67%/33% (2 : 1)
3 51, f Larynx (vocal fold+supraglottis) Mass +/+ Diffuse ly+plasma cell κ−, λ+ κ/λ: 5%/95% (1 : 19)
4 62, m Oral cavity (palate) Mass +/+
Diffuse+laminated
concentric
ly+plasma cell κ+, λ− κ/λ: 86%/14% (6 : 1)
5 31, m Larynx (ventricular fold, right) Mass +/+
Diffuse+laminated
concentric
ly+plasma cell κ+, λ+ κ/λ: 16%/84% (1 : 5)
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(a) (b)
(c) (d)
(e) Amyloid A (f) Amyloid P component
(g) ApoAI (h) Prealbumin
Figure 1: Continued.
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plasma cell infiltrate (Figures 1(i) and 1(j)). The cellular
infiltrate was, however, intensive enough in only one case
to raise the possibility of a local plasma cell neoplasm
(patient 4). IgH-PCR analysis was also performed, but
the results were inconclusive; therefore, the data were not
listed here.
3.3. Nano-HPLC-MS(MS) Analysis of Amyloid Mass. The
amyloid mass region of the dewaxed tissue slides were
scraped off and used for proteomic analysis, using high-
resolution nano-HPLC-MS/MS setup, as described above.
Amyloid deposits showed approximately 500 proteins
(detected with at least 2 unique peptides altogether in the five
samples). Among these, various IgG components including κ
and λ light chains were detected [14]. Figure 2 summarizes
the percent distribution for the 21 most abundant and two
low abundance proteins in the five cases studied. These
include ApoAIV, APC, apolipoprotein E (ApoE), and vitro-
nectin, which were previously proved to participate in the
formation of amyloid [1, 3]. Other amyloidogenic proteins,
like AA and PA, were also detected in low abundance, similar
to the IHC results (Figure 2). Surprisingly, both the κ and λ
light chains were present in each sample. Eight unique pep-
tides corresponding to the Ig kappa chain constant region
(IGKC_HUMAN) were detected. The Ig lambda chain con-
stant region was detected also by 8 peptides. In the samples,
peptides corresponding to the variable regions of the Ig
kappa and Ig lambda chains were also found in low abun-
dance. To determine total immunoglobulin content and the
ratio of the κ and λ light chains in the samples, label-free
quantitation was performed using the MaxQuant software,
utilizing peptides in the constant regions. The ratio of the
κ/(κ+λ) light chains in the studied samples is shown in
Table 3. Values close to 1 indicate κ dominance, while values
close to 0 indicate λ dominance. In patients 3 and 5, the
values were 0.12 and 0.02, respectively, suggesting λ domi-
nance. This ratio was 0.94 in patient 4 indicating κ domi-
nance. The remaining two cases (patients 1 and 2) had
similar κ/(κ+λ) ratios (0.26 and 0.29) suggesting lambda
dominance. Based on the label-free quantitative results, the
total immunoglobulin amount of the amyloid mass varied
between 2 and 9% in the cases analysed, while the total kappa
and lambda chain contents were between 0.1-7% and 0.4-5%,
(i) (j)
Figure 1: (a) HE staining, low power magnification. The photograph demonstrates the diffuse, infiltrating, type of amyloid deposition in
biopsy material of patient 2. See how the eosinophilic amyloid material surrounds and embeds the mucus ducts. (b) HE staining. This
midpower detail (patient 5) represents another form, the concentrically laminated nodular appearance of amyloid deposition. Note the
occasional multinucleated giant cells (arrows) surrounding the nodules and the lymphoplasmacytic infiltrate in between. (c) Congo red
staining, polarized light, high-power magnification. The biopsy specimen of patient 1 shows the laminated structure of the Congo red-
positive amyloid nodules with apple-green birefringence. (d) λ immunohistochemical staining, midpower photograph, patient 1. Note the
respiratory epithelium on the top and the immunopositive nodules showing different staining intensity and laminated structure. (e–h)
Immunopositivity for amyloid A, P component, ApoAI, and prealbumin, respectively, in patient 4. Note the variable staining intensity in
the amyloid material. (i, j) κ and λ mRNA-ISH on consecutive slides of patient 5. See the λ-dominant, centrally placed plasmacytic
population in (j).
Table 2: Immunohistochemical reaction of the four amyloidogenic
proteins and cytokeratin examined on the amyloid material of the
five cases. The intensity of the reactions was variable highlighting
the concentric laminar structure of the nodular mass. NA∗: data
are not available. Due to the lack of amyloid or tissue material, the
reactions were not evaluated. CK: pan-cytokeratin AE1-AE3, only
weak positivity∗∗.
Patient Prealbumin ApoAI Amyloid A
Amyloid P
component
CK∗∗
1 + + + + +
2 + + − − NA∗
3 NA∗ NA∗ NA∗ NA∗ NA∗
4 + + + + −
5 + + + + +
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respectively. Individual results of the examined cases are
summarized in Table 3. Changes in the amount of κ and λ
light chains were determined relative to the total amount of
all the proteins detected in the amyloid mass. We recalcu-
lated the values incorporating the variable regions of the
kappa and lambda chains as well. It resulted in minor
changes only and did not have an impact on the results.
4. Discussion
The neoplasm-mimicking clinical appearance and the most
frequent anatomical sites of localized amyloidosis are well-
known characteristics mainly from case studies [2, 22–26].
Our series of localized amyloidosis showed the previously
published features. Three of the five occurred in the larynx
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Figure 2: List and relative distribution of the top 21 and 2 low abundance proteins observed by nano-HPLC-MS(MS) and given in percent in
the five cases; normalized to the top 21 proteins. Known amyloidogenic proteins, like ApoAIV (5), LC κ and λ (14 and 15), ApoAI (21), PA
(102), and AA (194) partly examined by immunohistochemistry, were also present in the amyloid material in different concentrations. Note
that not just LCs but also ApoAIV and ApoAI with higher intensity and PA and AA with much less intensity also participated in the
formation of the lesion. The numbers at the bottom of the columns indicate the mean frequency of the particular protein.
Table 3: Summary of the nano-HPLC-MS(MS) results. Percents of total immunoglobulin, Ig κ chain constant region, Ig λ chain constant
region, and κ/(κ+λ) ratio were determined by label-free quantitation and normalized to total amyloid mass. The κ/(κ+λ) ratio of the cases
was determined by nano-HPLC-MS(MS) using label-free quantitation. Due to the presence of low abundance Ig components, data were
normalized to total amyloid mass, resulting in small numerical differences compared to Figure 2.
Age/gender Anatomic site
Nano-HPLC-
MS(MS) total
immunoglobulin (%)
Nano-HPLC-
MS(MS)
κ chain (%)
Nano-HPLC-
MS(MS)
λ chain (%)
Nano-HPLC-
MS(MS)
κ/(κ+λ)
1 61, male Larynx (vocal+ventricular fold) 2.82% 0.41% 1.16% 0.26
2 44, male Epipharynx 1.99% 0.39% 0.95% 0.29
3 51, female Larynx (vocal fold+supraglottis) 3.34% 0.40% 2.84% 0.12
4. 62, male Oral cavity (palate) 9.28% 6.89% 0.40% 0.94
5. 31, male Larynx (ventricular fold, right) 6.12% 0.10% 4.63% 0.02
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and the other two in the epipharynx and oral cavity (pala-
tum), respectively. Histological examination of the biopsies
explored common changes. On HE-stained slides, the amy-
loid material appeared either in the form of a diffuse eosino-
philic infiltrate embedding the normal tissue structures or
combined with concentrically laminated nodular form of
amyloid deposition (Figures 1(a) and 1(b)). This is probably
due to the different organization of the protein molecules in
the amyloid, but the details are not understood; these two dif-
ferent patterns of deposition are not widely examined and
not frequently reported features. None of the above patterns
linked to any specific light chains or other amyloidogenic
proteins by immunohistochemistry, all the proteins appeared
in both forms of deposition. Besides the occasional calcifica-
tion, foreign body type of giant cells was also visible mainly
around the nodular deposits. These cells are thought to par-
ticipate in amyloid material processing [3, 27]. Both forms
of depositions were Congo red-positive and showed birefrin-
gence under crossed polars with apple-green polarization
colour even after the KMnO4-trypsin pretreatment.
It is generally accepted that the cellular infiltrate in the
localized amyloidosis is monoclonal [8–11]. All the lesions
except case 4 in this study were hypocellular. Probably, this
was the reason of the failure of IgH-PCR analysis in charac-
terizing the clonality of the cellular infiltrate. The κ and λ
immunohistochemistry also did not produce reliable results
since the staining intensity in the cellular infiltrate and the
number of the cells were generally low even on the CD38-
stained slides (except case 4). Based on the intensity and
specificity of staining on the consecutive slides, reliable
results were obtained with the κ and λ mRNA-ISH. Image
analysis revealed κ or λ dominance in all but one sample sug-
gesting the clonal origin of the plasmacytic population.
Biopsy material from patient 2, however, showed 2 : 1 κ/λ
ratio which is in the normal range indicating the polyclonal
nature of the cellular infiltrate in this case. In patients 1, 3,
and 5, λ dominance was seen at a ratio of 4x, 19x, and 5x,
respectively (Table 1), while in patient 4 6x κ dominance
was calculated by the analysis. Despite the numerous liter-
ature data on the monoclonal nature of the lesion, some
cases—similar to our patient 2—are clearly polyclonal.
Moreover, many monoclonal examples, three cases from
localized amyloidosis and a nodular pulmonary amyloid-
osis series published earlier, revealed polyclonal cellular
infiltrate, which raises the possibility that some lesions
are not neoplastic [8, 28]. This seemingly contradicts the
suicide neoplasm theory [3].
The composition of amyloid material in localized amy-
loidosis is not extensively studied and not a published area
of histopathology. HPLC-MS analysis of the amyloid mate-
rial revealed κ dominance in patient 4 and λ dominance in
patients 1, 2, 3, and 5, respectively. All but one of these pro-
teomic results are in accordance with the dominance of the
plasma cell population determined by the mRNA-ISH; there-
fore, in these cases a localized clonal plasma cell disease
might be suggested in the background. Despite the frequently
obvious κ or λ dominance, no local or systemic neoplasm
could be identified in the clinical history of the patients. This
may draw the attention that a κ- or λ-dominant population is
not necessarily a neoplasm at the same time. We should
emphasize that besides the dominant form, the other light
chain was also present in the amyloid material, probably
due to the insudation from the blood plasma or true local
light chain production by the other plasma cell population.
In the biopsy sample of patient 2, λ dominance was measured
in the amyloid by HPLC-MS, which is in contrast to the poly-
clonal nature of the plasmacytic infiltrate defined by the
mRNA-ISH. This is interesting and obscure but not unique
since a similar case was published by Grogg et al. in a nodular
pulmonary amyloidosis series (case 9), where κ light and γ Ig
heavy chains were identified by mass spectrometry beside the
mixed plasma cell population [28]. The contrast between the
polyclonal plasmacytic population and λ dominance in the
proteomics in our case 2 may reflect on a different protein
synthesis activity of the κ- and λ-positive plasmacytic clones,
or it might be explained by the more intensive amyloidogenic
nature of the λ light chains. The immunohistochemical find-
ing of the amyloid was congruent with the results of the
HPLC-MS analysis in patients 3 and 4 and also identified
the other light chain (κ) in the otherwise λ-dominant amy-
loid material of patients 1 and 5. In these two later cases,
HPLC-MS also detected the κ chain. Both light chains in
approximately equal amounts were identified by the two
methods in the amyloid material of a lesion on the palate of
a patient [29].
HPLC-MS also showed that similar to the systemic
forms, the amyloid material in the localized amyloidosis
of the upper aerodigestive tract is by far not a homoge-
nous immunoglobulin mass but rather a mixture of struc-
tural, cytoskeletal, regulatory, or serum proteins with
different intensities in which the light chains sometimes
produce just a smaller part of the mass (Figure 2). Cyto-
keratins, vimentin, collagen, haemoglobin, apolipoproteins,
and albumin may all be derived partly from the serum or
from the surrounding tissue structures destroyed by the
accumulating amyloid mass. Moreover, both IHC and
HPLC-MS revealed three well-known, potentially amyloi-
dogenic proteins (AA, PA, and ApoAI) in the lesions,
but their primary amyloid-forming nature in the localized
amyloidosis of the upper aerodigestive tract has not been
proven yet.
Besides these, other proteins like ApoAIV, ApoE, APC,
and vitronectin, the well-known components of the so called
“universal amyloid proteome” in systemic amyloidosis, were
all identified in our localized amyloidosis cases with much
higher intensities than the former three [30]. ApoE, ApoAI,
ApoAIV, collagen, and vitronectin were also identified by
mass spectrometry in a nodular pulmonary amyloidosis
series published recently [28]. These facts may emphasize
the partly similar composition of the amyloid material in
the localized and systemic diseases; however, the true fibril-
forming components could be identified only by high-
resolution microscopic methods.
Although IHC indicated keratin just in two of the three
cases, HPLC-MS identified keratin 1, 10, 9, 14, and 5 in the
amyloid mixture of the samples. Sometimes the keratins
appeared with the highest intensities in the cases analysed;
however, we should emphasize that HPLC-MS or IHC could
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indicate only the presence and intensity of these proteins in
the mass and not their primary amyloid-forming nature.
Similar to the nodular pulmonary amyloidosis series
cited above, the intensity data of ApoAIV were also relatively
high in all the samples examined in this study which might
indicate its initiator role in the localized amyloidogenesis
[28]. Several years ago, a case of systemic amyloidosis of
two separate proteins (transthyretin and ApoAIV) with
distinct deposition patterns was described, and recently,
in our university, ApoAIV type of systemic amyloidosis
was discovered in a PACAP-KO mice strain, which all
may indicate the primary amyloidogenic potential of the
ApoAIV protein [31, 32].
HPLC-MS analysis, histology, and mRNA-ISH were
proved to be a powerful combination in the characterization
of these complex lesions. The frequent low intensity of the
immunoglobulins and high intensity of other proteins might
raise the latter’s primary role in the genesis of localized amy-
loidosis in the upper aerodigestive tract.
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